NYBC Ventures
NYBC Ventures is a $50M Boston-based early-stage life sciences venture capital fund launched in 2021 by New York Blood Center Enterprises to invest in blood, cellular therapy, and transfusion medicine companies across hematology, cell therapy, and infectious disease.
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What NYBC Ventures does
NYBC Ventures is a $50 million early-stage life sciences venture capital fund founded in 2021 and headquartered in Boston, Massachusetts. It operates as a wholly-owned corporate venture subsidiary of New York Blood Center Enterprises (NYBCe), a nonprofit blood products and transfusion services organization serving 75 million people and 400+ hospitals across nearly 45 countries. The fund invests in early- to mid-stage companies developing therapeutics, devices, and breakthrough solutions in four focus areas: hematology, transfusion medicine, cell therapy, and infectious disease. Its core differentiator is privileged access to NYBCe's research and manufacturing infrastructure, including the Lindsley F. Kimball Research Institute and Comprehensive Cell Solutions cell and gene therapy manufacturing unit.
The portfolio currently comprises more than 15 companies, including Akadeum, Aronora, AvenCell, Catenabio (Catena Bio), Cellular Origins, Functional Fluidics, HealthQuest Capital, Immusoft, KaloCyte, Lightning Bio, STRM.Bio, Thymmune, Star Therapeutics/Vega, Veralox, Vitestro, and Vittoria Bio, with newer additions spanning cell therapy manufacturing automation (Cellular Origins, UK), transfusion robotics (Vitestro, Netherlands), and RNAi therapeutics (City Therapeutics). Recent disclosed co-investments include the $40M Cellular Origins Series A led by Johnson & Johnson Innovation (December 2025) and the $99.5M City Therapeutics Series B (June 2026) co-led with Viking Global and Sofinnova.
The fund generates revenue through conventional VC economics: management fees on committed capital and carried interest on successful portfolio exits, supplemented by the strategic and reputational value its investments return to NYBCe. It is sales-led, sourced through NYBCe network referrals, industry conferences, and direct outreach, and led by General Partners Christopher D. Hillyer, MD (President/CEO of NYBCe) and Jay Mohr (EVP/CBO of NYBCe), with Managing Director Meg Wood, MPH and Senior Analyst Kuan Yu. The Board of Managers is chaired by John Rosenthal and includes biotech operators Jung Choi, Cristina Csimma, and David Kabakoff.
NYBC Ventures firmographics
Firmographics- Name
- NYBC Ventures
- Legal name
- NYBC Ventures
- Website
- https://www.nybcventures.org
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NYBC Ventures is a $50M Boston-based early-stage life sciences venture capital fund launched in 2021 by New York Blood Center Enterprises to invest in blood, cellular therapy, and transfusion medicine companies across hematology, cell therapy, and infectious disease.
- Ownership category
- akta.pro rank
NYBC Ventures industry classification
Industry- Product category
- Venture Capital
- NAICS
- Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industries
- Early-Stage Venture Capital (Series A/B) (FSANAAAB), Late-Stage Venture Capital (Series C+) (FSANAAAC)
Keywords
Where NYBC Ventures is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NYBC Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund Management and Carried Interest: NYBC Ventures generates returns through management fees on the $50M fund and carried interest on successful portfolio company exits. As a life sciences VC fund, returns are realized through equity appreciation and exits via acquisitions or IPOs of portfolio companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NYBC Ventures product offering
Product offeringCore offering
NYBC Ventures is a $50 million early-stage life sciences venture capital fund that invests in promising companies developing therapeutics, devices, and breakthrough solutions in blood and cellular therapies. The fund targets early to mid-stage biotech and medtech companies across hematology, cell therapy, transfusion medicine, and infectious disease. Portfolio companies receive equity capital plus strategic guidance and network access through New York Blood Center Enterprises (NYBCe).
Product overview
NYBC Ventures is a $50 million early-stage life sciences venture capital fund launched by New York Blood Center Enterprises (NYBCe). The fund invests in therapeutics, devices, and breakthrough solutions in blood and cellular therapies and related technologies. The portfolio includes investments in companies such as Akadeum, Aronora, Avencell, Catenabio, Cellular Origins, Functional Fluidics, HealthQuest Capital, Immusoft, KaloCyte, Lightning Bio, STRM.Bio, Thymmune, Vega Therapeutics (Star Therapeutics), Veralox, Vitestro, and Vittoria Bio. NYBC Ventures is not a product or technology company itself—it is an investment fund that supports external innovators.
Differentiator
Problem solved
Functional benefit
Products and services
- NYBC Ventures Fund A $50 million early-stage life sciences venture capital fund that invests in therapeutics, devices, and breakthrough solutions in blood and cellular therapies, including hematology, cell therapy, transfusion medicine, and infectious disease. Portfolio companies receive equity capital plus strategic guidance and access to NYBCe's research and manufacturing expertise.
Companies that use NYBC Ventures
Customer profileSegments1 record
Ideal customer profiles1 record
NYBC Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
NYBC Ventures partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- New York Blood Center Enterprises (NYBCe)coreNYBCe is the parent organization that launched NYBC Ventures with a $50M commitment. NYBCe has provided over 60 years of blood products and transfusion services, with its research arm Lindsley F. Kimball Research Institute and Comprehensive Cell Solutions (cell and gene therapy manufacturing) providing strategic expertise and network access to the fund's portfolio companies.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
NYBC Ventures competitors and assessment
Company assessmentDirect peers
- Pfizer Ventures: Corporate venture capital arm of Pfizer investing in early-stage therapeutics across multiple therapeutic areas. Comparable as a pharma-backed CVC deploying strategic capital into emerging biotech platforms, though with broader therapeutic scope than NYBC Ventures' blood/cell therapy focus.
- Novartis Venture Fund: Venture capital arm of Novartis investing in life sciences therapeutics and platform technologies. Comparable as a strategic CVC with deep scientific networks backing early-stage companies, though operating at significantly larger fund size and broader therapeutic mandate.
- Regeneron Ventures: Corporate venture arm of Regeneron investing in biotechnology companies. Directly comparable as a co-investor with NYBC Ventures in City Therapeutics' Series B; both deploy strategic capital into therapeutics with parent-company operational synergies.
- Johnson & Johnson Innovation (JJDC): Strategic venture capital arm of Johnson & Johnson. Directly comparable as a co-investor leading Cellular Origins' Series A alongside NYBC Ventures; both invest early in cell therapy and biomanufacturing platforms with corporate strategic intent.
- ARCH Venture Partners: Early-stage life sciences venture firm investing across therapeutics, platforms, and biomedical technologies. Comparable as a co-investor alongside NYBC Ventures in City Therapeutics; both back transformative biotech from inception, though ARCH operates at substantially larger fund scale.
- Sofinnova Investments: Sector-focused life sciences venture firm. Directly comparable as a co-investor in City Therapeutics' Series B; both back early-stage therapeutics with similar LP bases and exit strategies, with Sofinnova at materially larger fund size.
- 5AM Ventures: Early-stage life sciences venture capital firm investing in platform technologies and therapeutics. Comparable as a similarly-sized, science-driven life sciences VC targeting early-stage biotech with operating partner support, though without a corporate parent anchor.
- HealthQuest Capital: Healthcare growth equity and venture firm. Comparable given NYBC Ventures' board member David Kabakoff co-founded HealthQuest Capital, and HealthQuest appears in NYBC Ventures' portfolio — both target commercial-stage healthcare innovation with strategic investor networks.
- Versant Ventures: Healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics. Comparable as a sector-specialist life sciences VC building companies from inception, with similar thesis-driven approach but materially larger fund vehicles.
- Atlas Venture: Early-stage life sciences venture firm focused on building biotech companies from inception. Comparable as a similarly science-driven, therapeutics-focused VC investing at comparable check sizes into early-stage platforms and asset-centric biotech.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
NYBC Ventures social profiles
Digital presenceNYBC Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
NYBC Ventures leadership team
Management profileNumber of profiles
Profiles8 records
NYBC Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NYBC Ventures M&A and investment
M&A and investmentM&A
Investments19 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NYBC Ventures
What does NYBC Ventures do?
NYBC Ventures is a $50 million early-stage life sciences venture capital fund that invests in promising companies developing therapeutics, devices, and breakthrough solutions in blood and cellular therapies. The fund targets early to mid-stage biotech and medtech companies across hematology, cell therapy, transfusion medicine, and infectious disease. Portfolio companies receive equity capital plus strategic guidance and network access through New York Blood Center Enterprises (NYBCe).
Is NYBC Ventures a public or private company?
NYBC Ventures is a private company. It is classified as corporate owned and is currently operating.
When was NYBC Ventures founded?
NYBC Ventures was founded in 2021. It employs 11 to 50 people.
Where is NYBC Ventures based?
NYBC Ventures is headquartered in Boston, United States, in the North America region.
How does NYBC Ventures make money?
One revenue line is on record: fund Management and Carried Interest.
Who are NYBC Ventures's main competitors?
Direct peers on record are Pfizer Ventures, Novartis Venture Fund, Regeneron Ventures, Johnson & Johnson Innovation (JJDC), ARCH Venture Partners, Sofinnova Investments, 5AM Ventures, HealthQuest Capital, Versant Ventures and Atlas Venture.
Does NYBC Ventures have an API?
No public API is recorded for NYBC Ventures.
What industry is NYBC Ventures in?
NYBC Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 5239 and its SIC code is 6282.